PubMed Health⌕ Search

Biomedical subjects

A Kitagawa

Publications and source records attributed to A Kitagawa.

At least 37 records · Page 2Linked to original sources
PubMed1998

Protective effects of betamipron on renal toxicity during repeated cisplatin administration in rats and protective mechanism.

The protective effects of betamipron (BP, N-benzoyl-beta-alanine) against nephrotoxicity induced by repeated cisplatin injections were examined. The ratio of the kidney weight to body weight and the lipid peroxide level after treatment with cisplatin plus BP tended to be larger and lower than those after treatment with cisplatin plus alkaline solution, respectively. The blood urea nitrogen, serum creatinine and glutathione levels in the animals treated with cisplatin plus BP differed significantly from those in the animals treated with cisplatin plus alkaline solution. Furthermore, the mechanism of the preventive effects of BP was analyzed for cisplatin-induced nephrotoxicity. The concentration of cisplatin in the renal cortex significantly decreased with concomitant BP. BP inhibited the uptake of cisplatin into the renal cortex in a competitive manner in the same way as an anionic transport inhibitor, probenecid. The treatment with BP appears to be useful for the renal toxicity induced by repeated cisplatin administration.

Alanine↗
PubMed1997

Effects of betamipron on cisplatin nephrotoxicity and its pharmacokinetics in rats.

The protective effects of betamipron (BP, N-benzoyl-beta-alanine) on the nephrotoxicity of cisplatin were examined as indicated by body weight gain, ratio of kidney weight to body weight, blood urea nitrogen and serum creatinine levels in tumor-bearing rats. The results showed clearly that administration of BP 1 h after cisplatin treatment affords protection against the nephrotoxicity of cisplatin. Furthermore, the addition of BP to cisplatin had no apparent effect on the efficacy of cisplatin against Walker 256 carcinosarcoma cells in rats. In addition, no observed significant difference in plasma cisplatin concentration between cisplatin with alkaline solution and cisplatin with BP may be partly attributed to the decrease in the cisplatin exsorption to the intestine and its excretion to bile, and to an increase in cisplatin excretion to the urine.

Alanine↗
PubMed1997

Betamipron reduces cisplatin nephrotoxicity in rodents without modifying its antileukemic activity in mice.

Protective effects of betamipron (BP, N-benzoyl-beta-alanine), one of a series of N-acyl amino acids, on cisplatin-induced nephrotoxicity were examined. Since the damage observed in the kidney is localized to the proximal tubule cells, we investigated the influence of BP on urinary enzymes and excreta. Male Wistar rats and ddY mice were injected i.p. with 6 mg/kg and 16 mg/kg, respectively, of cisplatin combined with an i.p. 250 mg/kg BP dose. The toxicity of cisplatin as indicated by body weight gain, blood urea nitrogen, and serum creatinine levels was significantly (p < 0.05) suppressed by administration of BP after cisplatin treatment. The increase in urinary N-acetyl-beta-D-glucosaminidase activity, increase and subsequent decrease in gamma-glutamyl transferase activities, and increase in beta 2-microglobulin level observed after treatment with cisplatin were suppressed by administration of BP after cisplatin treatment. The combination of cisplatin and BP had no apparent effect on the efficacy of cisplatin against P388 leukemic cells in mice.

Acetylglucosaminidase↗
PubMed1996

Protective effects of N-benzoyl amino acids on cisplatin nephrotoxicity in rats.

The protective effects of N-benzoyl amino acids (NAAs) and piperacillin (PIP), anionic transport inhibitors, against the nephrotoxicity of cisplatin were examined in rats. Male Wistar rats were injected i.p. with 6 mg/kg of cisplatin combined with i.p. NAAs or PIP. Rats were sacrificed on day 5 after cisplatin injection to weigh the kidney and liver, and to determine blood urea nitrogen (BUN) and serum creatinine (serum Cr) levels. Treatments with NAAs were an effective means of protection against cisplatin-induced nephrotoxicity. The combination of cisplatin with NAAs containing a short and straight chain significantly suppressed (p < 0.05) the changes in body, kidney and liver weights, BUN and serum Cr. Further, betamipron (BP) at a 2000 mg/kg dose showed no apparent effect on the body, kidney and liver weights, BUN and serum Cr levels in rats. The combination of cisplatin with PIP caused a loss in body weight. The protective effects of PIP against cisplatin toxicity are inferior to those of BP when compared at 250 mg/kg doses.

Alanine↗
PubMed1996

Protective effect of N-benzoyl-beta-alanine against cisplatin nephrotoxicity in rats.

Prophylactic effects of N-benzoyl-beta-alanine (betamipron, BP), one of a series of N-acyl amino acids, were examined against cisplatin-induced nephrotoxicity. Male Wistar rats were injected i.p. with 6 mg/kg of cisplatin combined with an i.p. BP dose given at various times and various doses. Rats were sacrificed 5 days after cisplatin injection to weigh the kidney and liver, and to determine blood urea nitrogen (BUN) and serum creatinine (serum Cr) levels. Preliminary results suggest that treatment with BP is an effective means of protection against cisplatin-induced nephrotoxicity. Combination with BP reduced the weight loss following treatment with cisplatin. The ratios of the kidney and liver weights to the body weight in the animals treated with cisplatin followed later with BP are significantly different (p < 0.05) from those in the animals that received only cisplatin. The BUN and serum Cr levels in the animals treated with cisplatin followed from -1 to 4 hr, and from -4 to 4 hr later with 250 mg/kg BP dose and followed 1 hr later with from 250 to 1000 mg/kg, and from 250 to 2000 mg/kg BP doses differed significantly (p < 0.05) from those in the animals that received only cisplatin. Histological analysis of the kidneys confirmed the protective effect of BP.

Alanine↗
PubMed1995

[31P-MR spectroscopy of bone and soft tissue lesions].

We studied 24 patients with bone and soft tissue lesions using 31P-MR spectroscopy (MRS). On image selected in vivo spectroscopy (ISIS) localized spectra, spectroscopic parameters were calculated: PME/noise ratio, gamma NTP/noise ratio, PME/gamma NTP and total metabolite signals (TMS). PME/noise, PME/gamma NTP and TMS were higher in malignant lesions than in benign ones. We set the criterion for malignancy as follows: PME/noise > 2.0 and gamma NTP/noise > 2.0 and PME/gamma NTP > 1.0. The accuracy of this criterion was 0.91 for malignant lesions and 1.0 for benign lesions. In six malignant tumors, MR spectra were obtained before and after chemotherapy. They were compared with the degree of tissue degeneration evaluated on pathological specimens. TMS after chemotherapy were markedly reduced in 3 cases. TMS seemed to reflect the degeneration of tumors. It could be said that MRS is a useful tool in differentiating from benign tumor lesions malignant bone or soft tissue lesions and in monitoring the effect of chemotherapy.

Adolescent↗
PubMed1993

[Biliary lithotripsy using super fine cholangioscopy with the deviced bended sheath].

Percutaneous transhepatic cholangioscopy (PTCS) is an useful technique to evaluate or treat biliary diseases, although PTCS is an invasive method for the patients. We used 5 F or 7 F of super fine cholangioscopy to treat two cases of choledocholithiasis after surgery without dilatation of drainage tract. We developed different types of bended sheath for supplement of lack of angle system in this cholangioscope. Furthermore, by using bended sheath, cholangioscopic view improved, because saline was injected at the same time via the sheath. We emphasize that super fine cholangioscope with bended sheath is a safe and useful modality for evaluation of biliary disease.

Adult↗
PubMed1992

Kallikrein-producing cells in the rat pituitary and pineal gland.

By using an immunohistochemical technique, kallikrein-producing cells in the anterior pituitary of rats were identified to be the same as prolactin-producing cells. Kallikrein was localized at the Golgi apparatus, the rough endoplasmic reticulum and secretory granules. Kallikrein was also located in the perivascular cells of the pineal gland.

Animals↗
PubMed1991

Localization of kallikrein in rat pineal glands.

The presence of kallikrein mRNA has been reported in the pineal gland of rats. Using an antibody to rat tissue kallikrein, we immunohistochemically examined the localization of cell components producing tissue kallikrein in this gland. The kallikrein immunoreactive cells were scattered in the parenchyma of the pineal gland. Their cell bodies were polymorphic with cell processes and a large nucleus similar to that of the pinealocyte. Frequently immunoreactive materials were seen to be localized in the perivascular areas.

Animals↗
PubMed1990

Kallikrein- and prolactin-producing cells in the rat anterior pituitary are the same.

Kallikrein-positive cells in the anterior pituitary of female rats were identified to be the same as prolactin-producing cells by using an immunoelectron microscopic method. The kallikrein immunoreactivity was localized at the Golgi apparatus, the rough endoplasmic reticulum, and secretory granules, suggesting that kallikrein is synthesized in the prolactin-producing cells and also may be secreted into the blood vessels.

Absorption↗
PubMed1990

Immunohistochemical localization of kallikrein within the prolactin-producing cells of the rat anterior pituitary gland.

The localization of tissue kallikrein in the pituitary gland of rats was investigated by an immunohistochemical technique using antiserum against rat urinary kallikrein. Kallikrein-positive cells were detected in the anterior lobe of the pituitary of both male and female rats, but were not observed in the posterior lobe of the pituitary in either sex. The kallikrein-positive cells in the anterior pituitary of female rats in oestrus were found to correspond to the prolactin-producing cells, whereas the cells producing GH, LH and ACTH were negative for kallikrein. It is possible, therefore, that the tissue kallikrein may be involved in the production of prolactin and not that of the other anterior pituitary hormones, such as GH, LH, FSH, ACTH and TSH.

Animals↗
PubMed1985

Evaluation of isotope ratio (IR) mass spectrometry for the study of drug metabolism.

Isotope ratio (IR) mass spectrometry was evaluated for the study of drug metabolism and balance using 13C, 15N2-labelled antipyrine (AP) as a test drug. Rats were given 40 mg kg-1 (13C,15N2)AP intraperitoneally. Breath, urine, faeces and blood were collected. Except for breath, samples were combusted in sealed quartz tubes. The resulting CO2 and N2 were analysed for excess 13C and 15N, relative to pre-dose samples, by IR mass spectrometry. In addition, blood levels of AP and cumulative excretion of urinary AP metabolites were determined by gas chromatography/mass spectrometry/selected ion monitoring (GC/MS/SIM) and high-performance liquid chromatography (HPLC) respectively. Excess 13C and 15N levels in blood were comparable with observed levels of AP, and urinary recoveries of 13C (42%) were in good agreement with those calculated from HPLC data (45%). N-Demethylation, one of the important pathways of AP metabolism, was most rapidly determined by excess 13CO2 excretion in breath (8%). The IR mass spectral analysis complemented gas chromatographic/mass spectrum and HPLC analyses, and was less complex.

Animals↗
PubMed1978

Malignant melanoma of the lacrimal sac.

A case of malignant melanoma of the lacrimal sac in a 41-year-old woman is reported, which is propably the 12th one in the world literature. Dacryocystectomy is advisable at a localized stage. The importance of early diagnosis is discussed.

Adult↗